Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Regulatory Requisite Post Marketing Surveillance to Assess the Safety and Efficacy of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg, q.d.) in Korean COPD Patients: A 30-Day, Open Label, Non-interventional Study

Trial Profile

Regulatory Requisite Post Marketing Surveillance to Assess the Safety and Efficacy of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg, q.d.) in Korean COPD Patients: A 30-Day, Open Label, Non-interventional Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2013

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 04 Nov 2009 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 04 Nov 2009 Actual patient number (3021) added as reported by ClinicalTrials.gov.
    • 04 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top